Primary Lab Test for Methotrexate Levels
Serum methotrexate levels are measured using high-performance liquid chromatography (HPLC) or immunoassays like enzyme-multiplied immunoassay technique (EMIT) or fluorescence polarization immunoassay (FPIA). These tests quantify methotrexate concentration in blood plasma, guiding dose adjustments and toxicity monitoring in cancer or autoimmune treatments.[1][2]
When and How Often Are Levels Checked?
Levels are typically drawn 24, 48, and 72 hours after high-dose methotrexate infusion to ensure concentrations drop below 0.1-1.0 micromol/L for safe leucovorin rescue. Low-dose weekly regimens (e.g., rheumatoid arthritis) rarely require testing unless toxicity is suspected.[1][3]
What Do Results Mean?
Therapeutic levels vary: high-dose therapy targets peak >1,000 micromol/L at 1 hour, with delayed clearance (>0.1 micromol/L at 72 hours) signaling risk of nephrotoxicity or myelosuppression. Levels >10 micromol/L at 24 hours often prompt enhanced rescue.[2][4]
Alternatives or Related Tests
Red blood cell (RBC) methotrexate polyglutamate levels assess long-term intracellular accumulation via HPLC-MS/MS, useful for adherence in chronic low-dose use, unlike transient serum tests.[3][5] Renal function tests (creatinine, BUN) and complete blood counts complement monitoring.
Risks of Not Testing or Abnormal Levels
Delayed clearance risks severe toxicity: mucositis, hepatotoxicity, or death. Pre-test hydration and urine alkalinization prevent crystal nephropathy. Genetic factors like MTHFR variants can alter metabolism, prompting closer monitoring.[4][6]
[1]: UpToDate - Methotrexate monitoring
[2]: Medscape - Methotrexate Toxicity
[3]: ARUP Laboratories - Methotrexate Polyglutamates
[4]: ASCO Guidelines - High-Dose Methotrexate
[5]: LabCorp - Serum Methotrexate
[6]: FDA Label - Methotrexate